Drug intelligence / Profile preview

YT023

Development stage: Phase 2
Lead developer: International Peace Maternity and Child Health Hospital
Modality: Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intra-ovarian Injection

Overview

YT023 is an exosome-based therapy derived from umbilical cord mesenchymal stem cells (UC-MSCs). It is being developed by the International Peace Maternity and Child Health Hospital for the treatment of premature ovarian insufficiency (POI). The therapy is administered via intra-ovarian injection and is designed to restore ovarian function by delivering bioactive molecules, such as proteins and microRNAs, that promote cell survival and tissue regeneration within the ovarian microenvironment. It is currently being evaluated in a Phase 1/2 clinical trial (CURE-POI) to assess its safety and efficacy in women aged 20-39 with POI.

Other names: Umbilical cord mesenchymal stem cell-derived exosomesUC-MSC-Exos

Beyond the preview

Go deeper on YT023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YT023.

Explore the full profile